Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia
based on the clinical study FENOC, indicated that there is no significant difference in efficacy AICC and Eptacog alfa therapy in patients susceptible to this treatment. An analysis of the direct and indirect costs shows that the costs of the annual course of treatment of 142 patients in Russia are...
Saved in:
| Main Authors: | R. I. Yagudina, I. Yu. Zinchuk |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2015-03-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/44 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER
by: R. I. Yagudina, et al.
Published: (2015-03-01) -
PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2018-02-01) -
Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis
by: R. I. Yagudina, et al.
Published: (2015-03-01) -
RETRACTED: Opportunities of the method «Budget impact analysis» for performing pharmacoeconomic research
by: V. V. Ryazhenov, et al.
Published: (2022-06-01) -
PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)